Rein Therapeutics Email Format

Biotechnology ResearchTexas, United States11-50 Employees

Rein Therapeutics is a clinical-stage biopharmaceutical company pursuing therapies for orphan pulmonary and fibrotic diseases within the biotechnology research industry. The company is headquartered at 12407 North mo Pac Expressway 390, Austin, Texas 78758, United States, and employs between 11 and 50 people. LTI-03 is a synthetic peptide with dual actions aimed at supporting alveolar epithelial cell survival and inhibiting profibrotic signaling, with a Phase 2 trial for idiopathic pulmonary fibrosis anticipated in the first half of 2025. A second candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a trials for loculated pleural effusions and has received Orphan Drug Designation in the U.S. and E.U. as well as Fast Track designation in the U.S. Financial data indicate revenue in the range of $10 million to $25 million and total funding of $21 million; recent news notes a collaboration with Advancium Health Network in October 2024 and an exclusive option related to ALRN-6924, a previously developed oncology asset discontinued in 2023.

Get verified Rein Therapeutics emails free

Company overview Employee directory